Prediction of the Renal Organic Anion Transporter 1 (OAT1)- Mediated Drug Interactions for LY404039, the Active Metabolite of Pomaglumetad Methionil
Pharmaceutical Research · 2023
DOI: 10.1007/s11095-022-03464-y ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutical Research, 2023. Verfasst von Y Anne Pak und 9 weiteren Autor:innen. Beteiligte Einrichtung: Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, 46285, USA. Hauptthemen laut MEDLINE: Amino Acids, Cyclic S-Oxides, Bridged Bicyclo Compounds, Heterocyclic, Drug Interactions. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: Eli Lilly and Company.
Abstract (Originalsprache)
PURPOSE: The objective of this work was to demonstrate that clinical OAT1-mediated DDIs can be predicted using physiologically based pharmacokinetic (PBPK) modeling. METHODS: LY404039 is a metabotropic glutamate receptor 2/3 agonist and the active moiety of the prodrug pomaglumetad methionil (LY2140023). After oral administration, pomaglumetad methionil is rapidly taken up by enterocytes via PEPT1 and once absorbed, converted to LY404039 via membrane dehydropeptidase 1 (DPEP1). LY404039 is renally excreted by both glomerular filtration and active secretion and in vitro studies showed that the active secretion of LY404039 was mediated by the organic anion transporter 1 (OAT1). Both clinical and in vitro data were used to build a PBPK model to predict OAT1-mediated DDIs. RESULTS: In vitro inhibitory potencies (IC50) of the known OAT inhibitors, probenecid and ibuprofen, were determined to be 4.00 and 2.63 µM, respectively. Subsequently, clinical drug-drug interaction (DDI) study showed probenecid reduced the renal clearance of LY404039 by 30 to 40%. The PBPK bottom-up model, predicted a renal clearance that was approximately 20% lower than the observed one. The middle-out model, using an OAT1 relative activity factor (RAF) of 3, accurately reproduced the renal clearance of LY404039 and pharmacokinetic (PK) changes of LY404039 in the presence of probenecid. CONCLUSIONS: OAT1- mediated DDIs can be predicted using in vitro measured IC50 and PBPK modeling. The effect of ibuprofen was predicted to be minimal (AUC ratio of 1.15) and not clinically relevant.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, 46285, USA.
- Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, 46285, USA. mmposada@lilly.com.
- Division of Clinical Pharmacology, Department of Medicine, The University of Western Ontario, London, ON, Canada.
Förderung
- Eli Lilly and Company
Zitieren
APA
Pak, Y. A., Posada, M. M., Bacon, J., Long, A., Annes, W., Witcher, J., Mitchell, M., Tirona, R. G., Hall, S. D., & Hillgren, K. M. (2023). Prediction of the Renal Organic Anion Transporter 1 (OAT1)- Mediated Drug Interactions for LY404039, the Active Metabolite of Pomaglumetad Methionil. Pharmaceutical Research. https://doi.org/10.1007/s11095-022-03464-y
Vancouver
Pak YA, Posada MM, Bacon J, Long A, Annes W, Witcher J, et al. Prediction of the Renal Organic Anion Transporter 1 (OAT1)- Mediated Drug Interactions for LY404039, the Active Metabolite of Pomaglumetad Methionil. Pharmaceutical Research. 2023. doi:10.1007/s11095-022-03464-y
BibTeX
@article{Pak2023,
author = {Pak, Y Anne and Posada, Maria M and Bacon, James and Long, Amanda and Annes, William and Witcher, Jennifer and Mitchell, Malcolm and Tirona, Rommel G and Hall, Stephen D and Hillgren, Kathleen M},
title = {Prediction of the Renal Organic Anion Transporter 1 (OAT1)- Mediated Drug Interactions for LY404039, the Active Metabolite of Pomaglumetad Methionil},
journal = {Pharmaceutical Research},
year = {2023},
doi = {10.1007/s11095-022-03464-y}
}
EUVIMED